Two new drugs for lung cancer have moved a step closer to approval in the European Union, while US regulators have turned down a third treatment for the disease.
The European Medicines Agency (EMA) issued positive opinions on Friday for Aumseqa and Zybrivo, which are intended for different groups of patients with non-small cell lung cancer.
On Sunday, it emerged that the US Food and Drug Administration (FDA) had declined to approve ivonescimab, after the clinical trial supporting the application failed to show a statistically significant improvement in patients’ overall survival.
The decisions concern three different treatments. The two regulators did not reach conflicting rulings on the same drug.
The European decisions
Aumseqa (aumolertinib) was the first to receive a positive opinion from the EMA’s Committee for Medicinal Products for Human Use. It is a targeted therapy that works by blocking the EGFR protein when it carries specific mutations that help cancer cells grow. It is intended for certain adults with non-small cell lung cancer and EGFR mutations.
Zybrivo (sintilimab) is an immunotherapy for adults with non-squamous non-small cell lung cancer. It is proposed for use in certain patients in combination with chemotherapy.
The positive opinions are not yet final approvals. Before the two drugs can be marketed in the European Union, the European Commission must issue a decision.
Why the FDA said no
The application for ivonescimab, made by Summit Therapeutics, covered its use with chemotherapy in patients with advanced non-small cell lung cancer and specific mutations whose disease had progressed after earlier targeted therapy.
In the clinical trial, the combination cut the relative risk of the disease worsening or of death by 48 per cent compared with chemotherapy alone. However, the difference in overall survival did not reach the required level of statistical significance.
According to Summit, the FDA concluded that a benefit in delaying disease progression, without a sufficiently established benefit in overall survival, did not support a favourable balance of benefit and risk for this approval. The company says later analyses, with longer follow-up, show further encouraging results.
The decision does not mean the drug has been shown to be ineffective, or that its development will stop. It means the data submitted were not judged sufficient to approve this particular use.




